Drugs / [111In]-DOTA-h11B6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04116164 | Sep 2019 → Jul 2023 | castration-resistant prostate carcinoma, metastatic neoplasm | SpectronRX | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [111In]-DOTA-h11B6 | “This first-in-human phase 0 trial uses an 111In-radiolabeled anti-hK2 monoclonal antibody, [111In]-DOTA-h11B6, to credential hK2 as a potential target for prostate cancer treatment.” PMID 38782459 ↗ Jul 2024 |
| Modality | Monoclonal antibody | “This first-in-human phase 0 trial uses an 111In-radiolabeled anti-hK2 monoclonal antibody, [111In]-DOTA-h11B6, to credential hK2 as a potential target for prostate cancer treatment.” PMID 38782459 ↗ Jul 2024 |